本网站为了提高网站的便利性使用Cookie。
Cookie政策
同意
Font Size
S
M
L
Print
Print
咨询(English)
English
Japanese
我们的事业
研究开发
公司信息
关联公司
股东・投资者信息(English)
可持续发展(English)
What's New
Archives
2025/08/25
Announcement of Joint Venture Establishment and Shareholders Agreement Execution
2025/07/09
Nippon Kayaku Selected as a Constituent of all ESG Indices by GPIF
2025/06/12
Nippon Kayaku announces IBTROZI
TM
approved in the U.S. for patients with advanced
ROS1
-positive Non-Small Cell Lung Cancer
2025/06/02
Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advanced
ROS1
-positive Non-Small Lung Cancer at ASCO 2025
2025/05/30
Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
投资者关系
Archives
公司介紹視頻
NIPPON KAYAKU Group in Your Daily Life
Commemorating 100 Years of Sukima Ideas
PageTop